Welcome to Markets Desk, your midday read on what's moving markets and the broader economy.
Europe's defense spending surge is hitting a wall of credibility. Governments have pledged hundreds of billions, but investors are now asking the harder question — whether aging industrial bases can actually convert budget commitments into deliverable weapons systems and, ultimately, into earnings. The gap between appropriation and production is where the trade gets complicated.
Shifting to biotech, two small-cap names are making strategic pivots worth watching. XTL Biopharmaceuticals has closed its acquisition of Psyga Bio, formally exiting legacy operations and going all-in on psychedelic-assisted therapies — a sector that remains early-stage but is drawing real capital. Meanwhile, Liminatus Pharma has amended its merger agreement with InnocsAI, expanding the deal's scope to pull in next-generation cell therapy technology, broadening what had been a narrower oncology pipeline into something with more platform potential.
And in a story that says something about how the AI economy is actually being built, Nvidia — the nearly five trillion dollar company powering the entire artificial intelligence buildout — still charges its employees for cafeteria meals. While competitors pile on perks to win talent, Jensen Huang has built the world's most valuable company on a culture of discipline and performance, not amenities.
That's the tape. Markets Desk, signing off the floor.
